Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.05.2016 | ICS congress 2015 | Sonderheft 2/2016

European Surgery 2/2016

Resectability of rectal cancer after neoadjuvant treatment – current status

European Surgery > Sonderheft 2/2016
MD PhD M. Sabol, R. Donát, P. Chvalný, J. Palaj, D. Dyttert, P. Mračna, Š. Durdík
Wichtige Hinweise
The supplement is dedicated to Jubilee World congress of International College of Surgeons 2015.
The publishing was sponsored by the Ministry of Health of the Czech Republic.



The purpose of the study was to compare our experience to recent trends of multimodal treatment of patients with locally advanced rectal cancer.

Patients and methods

209 patients with histologically proven adenocarcinoma of the rectum were treated for 3 years by a multimodal approach in a single center. Patients were evaluated for clinical and pathologic response. The type of surgical procedure and the number of retrieved lymph nodes and postoperative complications were recorded.


Neoadjuvant Chemoradiotherapy (CRT) had a downstaging effect in more than half of our patients (50.61 %), and about one quarter of them achieved a complete pathologic response (22.22 %).


Preoperative CRT produced an encouraging down-staging effect with acceptable toxicity and perioperative complications.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Sonderheft 2/2016

European Surgery 2/2016 Zur Ausgabe